

*Sub F1*

hybridizing with a cDNA sequence, derived from the coding region of SEQ ID NO:1, under stringent conditions, wherein said GILR protein is capable of inhibiting apoptosis and stimulating lymphocyte activity.

*Sub G1*

--42 (New). The GILR protein of claim 41 which comprises an amino acid sequence with no more than ten sequence changes from the amino acid sequence of SEQ ID NO:2 and is capable of inhibiting apoptosis and stimulating lymphocyte activity.

*Ex*

--43 (New). A derivative of the GILR protein of claim 42, wherein said GILR protein is conjugated or complexed with molecules facilitating or enhancing the transport of said GILR protein across the cell membrane and wherein the derivative has the same or higher biological activity as said GILR protein.

*Sub G2*

--44 (New). A pharmaceutical composition for the inhibition of apoptosis in cells or for stimulating lymphocyte activation, comprising, as an active ingredient, the derivative of claim 43.

*Sub G3*

--45 (New). A pharmaceutical composition for the inhibition of apoptosis in cells or for stimulating lymphocyte

activation, comprising, as an active ingredient, the GILR protein of claim 42.

--46 (New). A pharmaceutical composition for the inhibition of apoptosis in cells or for stimulating lymphocyte activation, comprising, as an active ingredient, the GILR protein of claim 41.

--47 (New). A derivative of the GILR protein of claim 41, wherein said GILR protein is conjugated or complexed with molecules facilitating or enhancing the transport of said GILR protein across cell membrane and wherein the derivative has the same or higher biological activity as said GILR protein.

--48 (New). A pharmaceutical composition for the inhibition of apoptosis in cells or for stimulating lymphocyte activation, comprising, as an active ingredient, the derivative of claim 47.